RHBC
DGX icon

R.H. Bluestein & Co’s Quest Diagnostics DGX Stock Holding History

R.H. Bluestein & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,800
Closed -$246K – 370
2022
Q1 		$246K Hold
1,800
– – 0.01% 336
2021
Q4 		$311K Sell
1,800
-200
-10% -$30.4K 0.01% 312
2021
Q3 		$291K Sell
2,000
-1,500
-43% -$219K 0.01% 327
2021
Q2 		$462K Hold
3,500
– – 0.02% 239
2021
Q1 		$449K Hold
3,500
– – 0.02% 229
2020
Q4 		$417K Hold
3,500
– – 0.02% 217
2020
Q3 		$401K Hold
3,500
– – 0.02% 196
2020
Q2 		$399K Hold
3,500
– – 0.02% 178
2020
Q1 		$281K Sell
3,500
-600
-15% -$62.1K 0.02% 191
2019
Q4 		$438K Buy
+4,100
New +$428K 0.02% 179

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

R.H. Bluestein & Co's DGX Position: Q2 2022 in Review

R.H. Bluestein & Co sold out of Quest Diagnostics (DGX) in Q2 2022, closing a stake of 1,800 shares — an estimated $246K sold.

R.H. Bluestein & Co first reported a position in DGX in Q4 2019 and held it in 10 quarters. The position peaked at $462K in Q2 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

  • R.H. Bluestein & Co reported no remaining Quest Diagnostics position as of Q2 2022 after selling out during the quarter.
  • R.H. Bluestein & Co sold 1,800 Quest Diagnostics shares in Q2 2022, an estimated $246K.
  • R.H. Bluestein & Co first reported a position in Quest Diagnostics in Q4 2019 and held it in 10 quarters.
  • R.H. Bluestein & Co's Quest Diagnostics position peaked at $462K in Q2 2021.
  • 851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on R.H. Bluestein & Co's 13F filing for Q2 2022, filed 11 Aug 2022.